OBJECTIVES: To evaluate whether high levels of C-reactive protein (CRP) in serum are associated with greater risk of all-cause dementia or mortality in the oldest-old. DESIGN: Prospective. SETTING: Research clinic and in-home visits. PARTICIPANTS: Population-based sample of adults (N=227; aged 93.9+/-2.8) from The 90+ Study, a longitudinal cohort study of people aged 90 and older. MEASUREMENTS: CRP levels were divided into three groups according to the assay detection limit: undetectable (<0.5 mg/dL), detectable (0.5-0.7 mg/dL), and elevated (> or =0.8 mg/dL). Neurological examination was used to determine dementia diagnosis (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria). Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were computed using Cox regression, and results were stratified according to and apolipoprotein E4 (APOE4) genotype. RESULTS: Subjects with detectable CRP levels had significantly greater risk of mortality (HR=1.7, 95% CI=1.0-2.9), but not dementia (HR=1.2, 95% CI=0.6-2.1), 0.4 to 4.5 years later than subjects with undetectable CRP. The highest relative risk for dementia and mortality was in APOE4 carriers with detectable CRP (dementia HR=4.5, 95% CI=0.9-23.3; mortality HR=5.6, 95% CI=1.0-30.7). CONCLUSION: High levels of CRP are associated with greater risk of mortality in people aged 90 and older, particularly in APOE4 carriers. There was a trend toward greater risk of dementia in APOE4 carriers with high CRP levels, although this relationship did not reach significance. High levels of CRP in the oldest-old represent a risk factor for negative outcomes.
OBJECTIVES: To evaluate whether high levels of C-reactive protein (CRP) in serum are associated with greater risk of all-cause dementia or mortality in the oldest-old. DESIGN: Prospective. SETTING: Research clinic and in-home visits. PARTICIPANTS: Population-based sample of adults (N=227; aged 93.9+/-2.8) from The 90+ Study, a longitudinal cohort study of people aged 90 and older. MEASUREMENTS: CRP levels were divided into three groups according to the assay detection limit: undetectable (<0.5 mg/dL), detectable (0.5-0.7 mg/dL), and elevated (> or =0.8 mg/dL). Neurological examination was used to determine dementia diagnosis (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria). Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were computed using Cox regression, and results were stratified according to and apolipoprotein E4 (APOE4) genotype. RESULTS: Subjects with detectable CRP levels had significantly greater risk of mortality (HR=1.7, 95% CI=1.0-2.9), but not dementia (HR=1.2, 95% CI=0.6-2.1), 0.4 to 4.5 years later than subjects with undetectable CRP. The highest relative risk for dementia and mortality was in APOE4 carriers with detectable CRP (dementia HR=4.5, 95% CI=0.9-23.3; mortality HR=5.6, 95% CI=1.0-30.7). CONCLUSION: High levels of CRP are associated with greater risk of mortality in people aged 90 and older, particularly in APOE4 carriers. There was a trend toward greater risk of dementia in APOE4 carriers with high CRP levels, although this relationship did not reach significance. High levels of CRP in the oldest-old represent a risk factor for negative outcomes.
Authors: Luigi Ferrucci; Annamaria Corsi; Fulvio Lauretani; Stefania Bandinelli; Benedetta Bartali; Dennis D Taub; Jack M Guralnik; Dan L Longo Journal: Blood Date: 2004-11-30 Impact factor: 22.113
Authors: Winfried März; Hubert Scharnagl; Michael M Hoffmann; Bernhard O Boehm; Bernhard R Winkelmann Journal: Eur Heart J Date: 2004-12 Impact factor: 29.983
Authors: K Yaffe; K Lindquist; B W Penninx; E M Simonsick; M Pahor; S Kritchevsky; L Launer; L Kuller; S Rubin; T Harris Journal: Neurology Date: 2003-07-08 Impact factor: 9.910
Authors: Marianne J Engelhart; Mirjam I Geerlings; John Meijer; Amanda Kiliaan; Annemieke Ruitenberg; John C van Swieten; Theo Stijnen; Albert Hofman; Jacqueline C M Witteman; Monique M B Breteler Journal: Arch Neurol Date: 2004-05
Authors: Reijo S Tilvis; Mervi H Kähönen-Väre; Juha Jolkkonen; Jaakko Valvanne; Kaisu H Pitkala; Timo E Strandberg Journal: J Gerontol A Biol Sci Med Sci Date: 2004-03 Impact factor: 6.053
Authors: Ramit Ravona-Springer; Erin Moshier; James Schmeidler; James Godbold; Jimmy Akrivos; Michael Rapp; Hillel T Grossman; Michael Wysocki; Jeremy M Silverman; Vahram Haroutunian; Michal Schnaider Beeri Journal: J Alzheimers Dis Date: 2012 Impact factor: 4.472
Authors: Thomas M van Himbergen; Alexa S Beiser; Masumi Ai; Sudha Seshadri; Seiko Otokozawa; Rhoda Au; Nuntakorn Thongtang; Philip A Wolf; Ernst J Schaefer Journal: Arch Neurol Date: 2012-05
Authors: Jeremy M Silverman; James Schmeidler; Michal S Beeri; Clive Rosendorff; Mary Sano; Hillel T Grossman; José R Carrión-Baralt; Irina N Bespalova; Rebecca West; Vahram Haroutunian Journal: Neurology Date: 2012-08-15 Impact factor: 9.910
Authors: Ulrika K Eriksson; Nancy L Pedersen; Chandra A Reynolds; Mun-Gwan Hong; Jonathan A Prince; Margaret Gatz; Paul W Dickman; Anna M Bennet Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: Andrea L Metti; Kristine Yaffe; Robert M Boudreau; Mary Ganguli; Oscar L Lopez; Katie L Stone; Jane A Cauley Journal: J Am Geriatr Soc Date: 2014-04-02 Impact factor: 5.562
Authors: Jaroslav A Hubacek; Anne Peasey; Hynek Pikhart; Petr Stavek; Ruzena Kubinova; Michael Marmot; Martin Bobak Journal: Hum Immunol Date: 2010-01-25 Impact factor: 2.850